Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Oncology

• Publication date

  2016-09-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2015.64.8931PMID 27138582PMCID PMC6816000
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis

  2015cited by this paper
• Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

  2015cited by this paper
• PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.

  2015cited by this paper
• A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.

  2014cited by this paper
• In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

  2014cited by this paper
• PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• Time for more optimism in metastatic breast cancer?

  2014cited by this paper
• PD-L1 Expression in Triple-Negative Breast Cancer

  2014cited by this paper
• LBA23A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH ADVANCED UROTHELIAL TRACT CANCER

  2014cited by this paper
• Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).

  2014cited by this paper
• Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

  2014cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

  2012cited by this paper
• Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer

  2012cited by this paper
• Triple-Negative Breast Cancer: Adjuvant Therapeutic Options

  2011cited by this paper
• BRCA1/2 mutations and triple negative breast cancers.

  2010cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2009cited by this paper
• Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes

  2009cited by this paper
• Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

  2008influential reference
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype

  2007cited by this paper
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  2007cited by this paper
• The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

  2006cited by this paper
• Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

  2006cited by this paper
• Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

  2006cited by this paper
• Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

  2006cited by this paper
• Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

  2006cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

  2005cited by this paper
• Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1

  2002cited by this paper
• Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.

  1996cited by this paper

• Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1

  2026cites this paper
• Research Progress on Immunotherapeutics for Triple-Negative Breast Cancer from a Single-cell Perspective.

  2026cites this paper
• Pain spectrum in immune checkpoint inhibitor-related adverse events: evolution, characteristics and management challenges based on bibliometrics

  2026cites this paper
• Optimizing radiotherapy for early-stage breast cancer: A comparative SEER-based analysis of neoadjuvant, intraoperative, and postoperative approaches

  2026influential citation
• Comparing efficacy of neoadjuvant therapy of triple-negative breast cancer: A Bayesian network meta-regression analysis

  2026cites this paper
• Augmenting cuproptosis and anti-metastatic immunity in breast cancer by copper-based nanoplatform for synergistic immunotherapy via lactate metabolic reprogramming and hypoxia alleviation.

  2026cites this paper
• Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review

  2026cites this paper
• Immunotherapy Approaches for the Treatment of Triple-Negative Breast Cancer

  2026cites this paper
• Genetically engineered nanovesicles based anti-EphA2/CD3 bispecific antibody promotes T cell immune response for triple negative breast cancer treatment

  2026cites this paper
• CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy

  2026cites this paper
• Tumor-Associated Neutrophils and Desmoplastic Reaction in the Breast Cancer Tumor Microenvironment: A Comprehensive Review

  2026cites this paper
• Discovery of a Novel 1,4-Benzodiazepine Derivative as a Highly Selective ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer.

  2025cites this paper
• Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer

  2025cites this paper
• TNBC molecular subtypes and potential detection targets for biological therapy indications.

  2025cites this paper
• The Landscape of Potential Targeted Treatments and Chemotherapy Efficacy Biomarkers for TNBC

  2025cites this paper
• PLA2G16‐Mediated Tetracosatetraenoic Acid Rewires Fatty Acid Oxidation to Impair CD8+ T Cell Immune Function in Promoting Breast Cancer Lung Metastasis

  2025cites this paper
• Decoding Breast Cancer: Emerging Molecular Biomarkers and Novel Therapeutic Targets for Precision Medicine

  2025cites this paper
• Dual-Target Therapeutic Strategies in Triple-Negative Breast Cancer: Mechanistic Insights and Clinical Potential

  2025influential citation
• Recent Advancements in Immunotherapy for the Treatment of Metastatic Breast Cancer.

  2025cites this paper
• Synergistic Effects of Radiotherapy and PD‑1 Blockade in a Human‑Mimetic BRCAness Model of Triple-Negative Breast Cancer

  2025cites this paper
• Small molecule inhibitors for treating breast cancer: drug analysis based on the pathogenesis of breast cancer.

  2025cites this paper
• Targeting c‐Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple‐negative breast cancer

  2025influential citation
• Systemic chemotherapy in metastatic TNBC polarizes effector T cell differentiation

  2025cites this paper
• Exploiting artificial intelligence in precision oncology: an updated comprehensive review

  2025cites this paper
• Unleashing the potential role of tumor-associated NK cells as a novel immunotherapeutic target in triple-negative breast cancer

  2025cites this paper
• Construction of a cell model with membrane-surface expression of canine PD-1 and PD-L1 proteins in 293T cells by using eukaryotic expression systems

  2025cites this paper
• Genomic characterization of tumor mutational burden-high breast carcinomas

  2025influential citation
• Long-Term and Sustained Remission of Advanced Triple-Negative Breast Cancer with Large Chest Wall Lesions after Transient Chemoimmunotherapy: A Case Report

  2025cites this paper
• A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer

  2025cites this paper
• Divide and Conquer—Targeted Therapy for Triple-Negative Breast Cancer

  2025cites this paper
• Predicting the response to immunotherapy from gene expression data in HER2-negative breast cancer

  2025influential citation
• Dostarlimab and niraparib in primary advanced ovarian cancer.

  2025cites this paper
• ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.

  2025cites this paper
• Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Anti-tumor Immunity and Improve Immunotherapy Efficacy.

  2025cites this paper
• Comparative analysis of PD-L1 expression and tumor-infiltrating lymphocytes between primary breast cancer and matched metastatic lesions: implications for immunotherapy

  2025cites this paper
• Immunotherapy for triple-negative breast cancer: current trends and future prospects

  2025cites this paper
• Immunotherapy in breast cancer: current landscape and emerging trends

  2025cites this paper
• Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer

  2025influential citation
• A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer

  2025cites this paper
• An Updated Review of Disparities in Postmastectomy Breast Reconstruction: Causes, Consequences, and Strategies for Promoting Health Equity

  2025cites this paper
• Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis

  2025cites this paper
• Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application

  2025cites this paper
• Liquid biopsy in TNBC: significance in diagnostics, prediction, and treatment monitoring

  2025cites this paper
• SLAMF1 expression in breast cancer cells delays tumor growth in vivo

  2025influential citation
• Enhancing Antitumor Efficacy of MUC1 mRNA Nano-Vaccine by CTLA-4 siRNA-Mediated Immune Checkpoint Modulation in Triple Negative Breast Cancer Mice Model

  2025cites this paper
• Construction and validation of predictive model based on endoplasmic reticulum stress-related genes for triple-negative breast cancer

  2025cites this paper
• MiRNA affects the advancement of breast cancer by modulating the immune system's response.

  2025cites this paper
• From bench to knowledge graph: mapping the global evolution of PD-1/PD-L1 immunotherapy in gastric cancer.

  2025cites this paper
• Evaluation of the Clinical Impact of Immune Checkpoint Inhibitors (Atezolizumab and Pembrolizumab) in the Treatment of Triple-Negative Breast Cancer: A Meta-Analysis and Review of Literature

  2025influential citation
• Development and validation of a TOP2A based index clinical model for kidney renal clear cell carcinoma

  2025cites this paper
• A comprehensive review on targeted therapies for triple negative breast cancer: an evidence-based treatment guideline

  2025cites this paper
• Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer

  2025cites this paper
• Quantitative proteomics analysis of triple-negative breast cancers

  2025cites this paper
• The clinical potential of PDL-1 pathway and some related micro-RNAs as promising diagnostic markers for breast cancer

  2025cites this paper
• Predictors of Immunotherapy Response in Triple Negative Breast Cancer

  2025cites this paper
• Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

  2025cites this paper
• Genetically engineered macrophages reverse the immunosuppressive tumor microenvironment and improve immunotherapeutic efficacy in TNBC.

  2025cites this paper
• Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy

  2025cites this paper
• Unveiling the role of SYNGR4 in breast cancer development: a novel target for immunotherapy

  2025cites this paper
• Neurological symptom management in breast cancer meningeal carcinomatosis

  2025cites this paper
• Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer.

  2025cites this paper
• Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer Systematic Review

  2025cites this paper
• The Role of Immunotherapy and Immune Modulators in Hormone-Positive Breast Cancer: Implications for Localized and Metastatic Disease

  2025cites this paper
• Shiny-MAGEC: A Bayesian R shiny application for meta-analysis of censored adverse events

  2025cites this paper
• Therapeutic potential of triple-negative breast cancer immune checkpoint blockers: A 21-year bibliometric analysis

  2025cites this paper
• New progress in imaging diagnosis and immunotherapy of breast cancer

  2025cites this paper
• Fundamental knowledge and research regarding the role of immunity in triple-negative breast cancer from 2014–2024: A bibliometric analysis

  2025cites this paper
• Integrative Analysis of DNA Methylation and microRNA Reveals GNPDA1 and SLC25A16 Related to Biopsychosocial Factors Among Taiwanese Women with a Family History of Breast Cancer

  2025cites this paper
• A bibliometric and visual analysis of the impact of senescence on tumor immunotherapy

  2025cites this paper
• Unveiling the Landscape of PD-L1 Expression and Tumor-Infiltrating Lymphocyte Subtypes in Advanced Triple-Negative Breast Cancer in Brazil

  2025cites this paper
• Perturbing local steroidogenesis to improve breast cancer immunity

  2025cites this paper
• Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study

  2025cites this paper
• Immunotherapy-Based Combination Therapy for the Successful Treatment of Coexisting Primary and Axillary Accessory Breast Cancers: A Case Report

  2025cites this paper
• Current Status of Immune Checkpoint Inhibitors and Treatment Responsive Biomarkers for Triple‐Negative Breast Cancer

  2025influential citation
• Advances in TIL therapy: Expanding the horizons beyond melanoma.

  2025cites this paper
• Targeting LAT1 with JPH203 to reduce TNBC proliferation and reshape suppressive immune microenvironment by blocking essential amino acid uptake

  2025cites this paper
• The Combination of CD300c Antibody with PD-1 Blockade Suppresses Tumor Growth and Metastasis by Remodeling the Tumor Microenvironment in Triple-Negative Breast Cancer

  2025influential citation
• Immunotherapy in Triple-Negative Breast Cancer

  2025influential citation
• Role of immunotherapy in early breast cancer: past, present, and future

  2025influential citation
• Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform

  2025cites this paper
• Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee

  2025cites this paper
• Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms

  2025cites this paper
• Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy

  2025cites this paper
• Therapeutic Indications of Pembrolizumab in Eight Common Cancers: Current Evidence and Future Directions

  2025cites this paper
• Immunotherapy and combination treatments for triple-negative breast cancer: a Scopus bibliometric perspective.

  2025cites this paper
• Advances in breast cancer therapy: "Exploring the therapeutic potential of CDK 4/6 inhibitors and their clinical impact."

  2025cites this paper
• Application of Immune Checkpoint Inhibitors in Cancer

  2025cites this paper
• Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study

  2025cites this paper
• Revolutionizing Breast Cancer Therapeutics: Intersecting Frontiers of Precision Medicine, Nanotechnology, and Drug Delivery Innovations

  2025cites this paper
• The clinicopathological and prognostic significances of CMTM6 and PD-L1 expression in breast cancer

  2025cites this paper
• Efficacy of postoperative immunotherapy on MPM patients after CRS + HIPEC: A single‐center retrospective study based on propensity score matching

  2025cites this paper
• Breast Cancer Immunotherapy: A Team Science Approach.

  2025cites this paper
• Targeting the tumor microenvironment in triple-negative breast cancer: Biological insights and therapeutic opportunities.

  2025cites this paper
• Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer

  2025influential citation
• Immunochemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Prospective Randomized Trials

  2025cites this paper
• Immune checkpoint inhibition in breast cancer: targeting PD-1/PD-L1 pathway for therapeutic advances

  2025influential citation
• Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study

  2025cites this paper
• Tumor microenvironment and immunotherapy for triple-negative breast cancer

  2024cites this paper
• Integrated immune-related gene signature predicts clinical outcome for patients with Luminal B breast cancer

  2024cites this paper
• Disrupted Lipid Metabolism, Cytokine Signaling, and Dormancy: Hallmarks of Doxorubicin-Resistant Triple-Negative Breast Cancer Models

  2024cites this paper